Michael Method
Chief Medical Officer Bicycle Therapeutics
Dr. Michael Method is Chief Medical Officer at Bicycle Therapeutics, leading clinical development across the company’s oncology portfolio, including next-generation Bicycle® Radioconjugates. With more than three decades of experience in oncology drug development, he has held senior leadership positions at Karyopharm Therapeutics, ImmunoGen and Eli Lilly, overseeing programmes from first-in-human studies through to registration and commercialization. A former academic gynecologic oncologist and Director of Gynecologic Oncology at Indiana University School of Medicine, Michael combines deep clinical expertise with extensive experience in translational medicine, regulatory strategy and global clinical development of innovative cancer therapies.
Seminars
Experience a fast-paced debate, where isotope specialists will each present the strongest case for their radionuclide before joining a moderated discussion comparing clinical evidence, manufacturing readiness, supply considerations and commercial potential. Hear contrasting perspectives, challenge conventional thinking and take part in the discussion as the audience helps determine which isotope will define the next five years of TRP development.
- Comparing the scientific, clinical, manufacturing and commercial advantages of emerging isotopes including Actinium-225, Lead-212, Copper-67, Terbium, Astatine-211 and Lutetium-177
- Evaluating which radionuclides are best positioned to win across therapeutic efficacy, supply scalability, dosimetry flexibility, theranostic integration and global clinical applicability
- Challenging each isotope expert to defend why their radionuclide will become the hottest, most commercially impactful and most clinically transformative isotope over the next five years
- Assessing the therapeutic potential of Lead-212 and the clinical rationale supporting its continued development
- Exploring the logistical and supply challenges associated with short half-life isotopes and how developers can successfully navigate them
- Understanding the balance between operational complexity and potential clinical advantages when selecting radionuclides
